// STATE LEGISLATION TRACKER

California AB 3063: Pharmacies: compounding.

⚖️ NEUTRAL for peptide users 👤 LOW user impact 📜 Status: Vetoed

State: California
Bill: AB 3063
Filed: 2024-02-16
Read the bill: OpenStates →
Last reviewed: 2026-10-02

Plain-English Summary

AB 3063 would have treated adding flavoring to a manufactured drug as not being pharmacy compounding if certain conditions were met. It was vetoed, so it does not change access to compounded peptides, sterile injectables, telehealth prescribing, NP/naturopath scope, controlled substances, or prescription monitoring.

Key Points

No direct change for compounded peptide prescribing or dispensing
Focused on medication flavoring, not sterile injectable compounding
Would have created a California exception from USP compounding rules
Does not expand telehealth or prescriber scope
Does not affect controlled substances or PDMP rules

What to Watch For

Note California remains aligned with USP compounding standards after the veto.

Concern Future attempts to carve out exceptions from USP rules could affect broader compounding policy.

Note Peptide patients using sterile injectable compounds should not expect access changes from this bill.

Where the Bill Stands

The Legislature passed AB 3063, but the Governor vetoed it on September 27, 2024, so it did not become law.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-10-02 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws